Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DICERNA PHARMACEUTICALS, INC.

(DRNA)
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Shareholder Alert: Ademi LLP investigates whether Dicerna Pharmaceuticals, Inc. has obtained a Fair Price in its going private transaction with Novo Nordisk

11/18/2021 | 10:59am EST

MILWAUKEE, Nov. 18, 2021 /PRNewswire/ -- Ademi LLP is investigating Dicerna (Nasdaq: DRNA), for possible breaches of fiduciary duty and other violations of law in its transaction with Novo Nordisk. 

Click here to learn how to join the action: https://www.ademilaw.com/case/dicerna-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

Ademi LLP alleges Dicerna's financial outlook and prospects are excellent and yet Dicerna shareholders will receive only $38.25 per share in cash, which represents a total equity value of $3.3 billion. The merger agreement unreasonably limits competing bids for Dicerna by prohibiting solicitation of further bids, and imposing a significant penalty if Dicerna accepts a superior bid. Dicerna insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Dicerna's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Dicerna.

If you own Dicerna common stock and wish to obtain additional information, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, or https://www.ademilaw.com/case/dicerna-pharmaceuticals-inc.                       

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-dicerna-pharmaceuticals-inc-has-obtained-a-fair-price-in-its-going-private-transaction-with-novo-nordisk-301428275.html

SOURCE Ademi LLP


ę PRNewswire 2021
All news about DICERNA PHARMACEUTICALS, INC.
2021Dicerna Pharmaceuticals Coverage Dropped by Chardan After Novo Nordisk Closes Acquisiti..
MT
2021Chardan Drops Coverage on Neutral-Rated Dicerna Pharmaceuticals on Acquisition by Novo ..
MT
2021DICERNA PHARMACEUTICALS, INC.(NASDAQ : DRNA) dropped from S&P Global BMI Index
CI
2021DICERNA PHARMACEUTICALS, INC.(NASDAQ : DRNA) dropped from S&P TMI Index
CI
2021DICERNA PHARMACEUTICALS, INC.(NASDAQ : DRNA) dropped from S&P Biotechnology Select Industr..
CI
2021Novo Nordisk Completes Dicerna Pharmaceuticals Acquisition
MT
2021DICERNA PHARMACEUTICALS : Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acq..
PU
2021DICERNA PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Notice o..
AQ
2021Novo Nordisk Closes on $3.3 Billion Acquisition of Dicerna Pharmaceuticals
MT
2021Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
BU
More news
Analyst Recommendations on DICERNA PHARMACEUTICALS, INC.
More recommendations